Tumour metastasis is the major cause of breast cancer mortality. Myricetin, a natural polyphenol, is found in teas, wines, and berries. The pharmacodynamic action and molecular mechanism of myricetin on breast cancer metastasis remain unknown. Here, we investigated the effect of myricetin on MDA-Mb-231Br cell viability, migration, invasion, and 4T1 mouse lung metastasis mouse models. MMP-2/9 protein expression and ST6GALNAC5 expression were analysed using western blot assays and quantitative real-time polymerase chain reaction, respectively. Cell migration and invasion were detected by wound-healing and Boyden transwell assays. The antimetastatic effect in vivo was evaluated by lung metastasis model. Myricetin significantly decreased the activities of MMP-2/9 and mRNA levels of ST6GALNAC5. In addition, the migration, invasion, and adhesion were effectively inhibited in a concentration-dependent manner.
| INTRODUCTION
Breast cancer metastasis is the second leading cause of cancer-related death in woman, with a mortality rate greater than 2.1 per million cases annually worldwide (Tevaarwerk et al., 2013) . About 4,292,000 newly diagnosed invasive cancer cases are expected to be occurred in 2015 in China, and it is predicted that breast cancer account for 15% in women (Chen et al., 2016) . The published SEER cancer statistics review of 18 areas in the United States from 2004 to 2010 show that the 5-year relative survival rates of all malignant cancers significantly declined, especially move into the distant origins. Although the survival rate of breast primary cancer is close to 100%, but it will decrease sharply to only 25% once distant metastasis happened (American Cancer Society, 2015) . Metastatic cancer will develop brain metastases between 20% and 40% of all patients according to the large autopsy studies. In most cases, advanced breast cancer patients have metastases in the lung, liver, and bone before brain metastases (Weil, Palmieri, Bronder, Stark, & Steeg, 2005) . Current therapeutic options such as surgery, stereotactic radiosurgery, whole brain radiotherapy, and chemotherapy are mostly palliative and fail in providing significant progress in treating breast cancer brain metastasis (BCBM; Freedman & Anders, 2012) . Prevention of cancer metastasis at early stages is a key factor for improving patient survival.
The blood-brain barrier (BBB) and the blood-tumour barrier preventing penetration of drugs into brain tumour site. They are the major obstacles for effective chemotherapeutic activity against BCBM.
Undesired chemicals are prevented by BBB, which is a protective layer in brain. Less than 2% of anticancer drugs targeting brain metastases enter clinical research because of low absorption efficiency in the brain (William & Boado, 2007) . Natural polyphenols, a group of phytonutrients with low toxicity, exist in our diet generally, and their Abbreviations: BBB, blood-brain barrier; BCBM, breast cancer brain metastasis; BTB, the blood-tumour barrier; DMEM, Dulbeccos Modified Eagle Media; DMSO, dimethyl sulfoxide; ECM, extracellular matrix; FBS, fetal bovine serum; MMP-2/9, matrix metalloproteinase; PAGE, polyacrylamide gels; SDS, sodium dodecyl sulfate chemopreventive activities and antimetastatic abilities have been widely discussed in the last 10 years (Mocanu, Nagy, & Szollosi, 2015) . Many bioactive polyphenols can traverse the BBB. The application of natural polyphenols shows promise in animal models of brain tumours. Here, we investigated a potential antimetastatic polyphenol, myricetin. Myricetin is found in teas, wines, berries, fruits, and medicinal plants, and it exhibits both anti-inflammatory (Grenier, Chen, Ben, Fournier-Larente, & Morin, 2015) and antioxidant (Bennett, Caldwell, McPhail, Morrice, & Duthie, 2004) properties. Studies have reported that myricetin inhibits (matrix metalloproteinase) MMP-2 expression in colon cancer cells (Ko, Shen, Lee, & Chen, 2005) and blocks the invasion and migration of glioblastoma cells into surrounding tissues (Chiu, Shen, Chow, & Chen, 2010) . In vivo experiments have demonstrated that myricetin can enhance tumour radiosensitivity (Zhang, Wang, Liu, Zhao, & Ming, 2014) and chemosensitivity . The antimetastatic effects of myricetin on breast cancer cells, especially for brain metastasis have not been reported previously.
Besides, a previous study has reported that myricetin can cross the BBB (Zhang et al., 2011) , which supports its use in the treatment of brain diseases.
Metastasis of breast cancer from the primary tumour site to a distant site (the brain and the lungs) is the major cause of death (Irvin & Carey, 2008) . Breast cancer metastasis is a multistep process, and this process requires escape of the primary tumour, invasiveness, intravasation, circulation, and colonization. Various proteolytic enzymes are highly expressed in the border of tumour stroma, provide the passage for cells to invade the nearby tissue, and facilitate the degradation of extracellular matrix (ECM) components. MMP-2 and MMP-9 are closely related to the migrant and invasive ability of cancer cells and are present in various malignant tumours (Yamamoto, H. et al., 2001) . The ST6GALNAC5 gene is discovered to be specifically expressed in the brain metastatic cell lines and up-regulated in patients with brain metastatic neoplasm (Bos et al., 2009 ). Functional validation experiments indicated an important role for this gene in facilitating the passage of cancer cells through the BBB to promote brain metastasis (Lorusso & Rüegg, 2012) . Brain metastasis formation was promoted based on high expression of ST6GALNAC5 in specific cell lines, whereas inhibition of ST6GALNAC5 expression could decrease the ability to cause brain metastasis. Accordingly, inhibition of cancer invasion and metastasis through regulation of MMP activities and ST6GALNAC5 gene expression could promote the development of therapeutic strategies against metastatic breast cancer. Therefore, it is imperative to identify new drugs or treatments for decreasing MMP-2/9 activity and ST6GALNAC5 expression. To further confirm the antimetastatic effect of myricetin in vivo, a mature lung metastatic model was employed. This metastatic model provides the advantages of rapid model maturity, specificity of metastasis endpoints, and high success rates once cells injected into each mouse (Khanna & Hunter, 2005) .
The aim of the previous study was to investigate the effects of Health Science Center, Beijing, China) were cultured in DMEM containing 10% FBS supplemented with 1% penicillin-streptomycin maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . 
| MTT assay

| Cell invasion and migration assays
The invasiveness of MDA-Mb-231Br cells was detected using 
| Gelatin zymography
The activities of MMP-2 and MMP-9 in the cultural medium were assessed by the zymographic analysis. The collected media were mixed with sodium dodecyl sulfate (SDS) sample buffer without boiling or reduction and separated on 8% SDS-polyacrylamide gels containing 1% gelatin at 4°C. Subsequently, the gels were washed with 2.5% Triton X-100 and then incubated in reaction buffer (50 mM Tris-HCl [pH 7.6], 5 mM CaCl 2 , 1 μM ZnCl 2 , and 0.02% Brij35) for 18-24 hr at 37°C. Finally, the gels were stained with 0.25% (w/v) Coomassie Brilliant Blue R-250 and destained with 20% methanol and 10% acetic acid. White lysis zones indicating gelatinase activities of MMP-2 and MMP-9 were visualized as clear bands against a blue background.
| qRT-PCR analysis of MMP-2/9 and ST6GALNAC5
Total RNA was isolated using the Nucleospin RNA II kit according to the manufacturer's instructions (Macherey-Nagel, Hoerdt, France). 
| Statistical analyses
Each experiment was performed at least three times. Average values and standard deviation of the results are presented as the mean ± SD.
Statistical analyses were performed using IBM SPSS 20 software, and the data were analysed using one-way analysis of variance followed by the Tukey test. Differences were considered significant when p < .05. 
| Myricetin inhibited the migration of MDA-Mb231Br cells
Cell migration is an essential step in cancer metastasis. As shown in These data revealed that myricetin inhibits MDA-Mb-231Br cell migration in a concentration-dependent manner.
| Myricetin inhibited the invasion of MDA-Mb231Br cells
To investigate the inhibitory effect of myricetin on the invasion of MDA-Mb-231Br cells, the invasive ability of tumour cells was measured by transwell chamber containing matrigel-coated insert.
According to the results in Figure 2d These results suggested that myricetin has an inhibitory effect on ST6GALNAC5 expression.
| In vivo antimetastatic activity of myricetin
A 4T1 mouse lung metastasis model was used to evaluate the antimetastatic potential of myricetin in vivo. As shown in Figure 4c ,d, mice treated with myricetin exhibited smaller numbers of tumour (Zhou, Bennett, & Zhou, 2016) . Research has shown that natural phytochemicals containing phenolic compounds in food may provide antimetastatic effects but with less toxicity than chemotherapeutic agents (Weng & Yen, 2012) . In our study, we illustrated that the natural polyphenol myricetin could inhibit the migration and inva- The data are expressed as the mean ± SD (n = 9, for control: n = 6). *p < .05 and **p < .01 (compared with vehicle group) [Colour figure can be viewed at wileyonlinelibrary.com] abilities in ECM degradation and tissue remodeling. We have made a further summary of the roles of MMPs in breast cancer metastasis (Ci et al., 2016) . Cell migration and invasion are closely associated with the enhanced activation of MMP-2 and MMP-9. A previous study showed that myricetin inhibits the invasion of human glioblastoma cells through inhibition of ERK-dependent COX-2/PGE2 activation and MMP-9 activity (Chiu et al., 2010) . In addition, myricetin significantly decreased MMP-1, MMP-2, and MMP-8 activities in chronic periodontitis has been reported. The results showed that myricetin significantly reduced the MMP-2 activity at 10 and 50 μM and reduced the MMP-1 and MMP-8 activities at 50 μM (Ko, 2012) . To further explore the inhibitory effect of myricetin on breast cancer metastasis, the activity of MMP-2/9 in MDA-Mb-231Br cells was evaluated. Our study demonstrated that myricetin also down-regulated the activities and expression of MMP-2 and MMP-9 in a concentration-dependent manner, and the effective concentration of myricetin was 5 μM, which is lower than mentioned before (10 μM). Recent research has shown that across the BBB requires further mediators, including the brain-specific sialyltransferase ST6GALNAC5. Correspondingly, the ability to colonize other organs requires additional mediators (Bos et al., 2009) . We demonstrated for the first time that natural polyphenolic compounds can inhibit ST6GALNAC5 expression and prevent the formation of brain metastasis.
Moreover, treatment with myricetin (50 mg/kg) could effectively inhibit breast cancer lung metastasis in mice (Figure 4) , illustrating its potential antimetastatic activity in vivo. Myricetin seems to block cancer metastasis at a relative low concentration, compared with that of resveratrol and luteolin. In our study, the effects of myricetin on lung metastasis in 4T1 Balb/c mice were evaluated, and an 82% reduction in the tumour metastasis was observed for mice receiving myricetin (50 mg/kg) compared with that of the vehicle. A previous study reported that treatment with 200 mg/kg resveratrol induced an 85% decrease in metastasis to the lungs (Lee et al., 2012) , and oral administration (50 mg/kg) of luteolin significantly suppressed about 70% tumour nodules by colon tumour cells in the same model (aHoYoung Kim et al., 2013) . Taken together, our data indicate that a similar dose of myricetin showed a better efficacy for inhibiting pulmonary metastasis of breast cancer. However, the ability of myricetin to inhibit metastasis in an orthotopic implantation model with MDA-Mb-231Br cells in nude mice needs further research, and more animal studies should be performed to better understand whether myricetin would be useful for combating metastatic breast cancer not only in animals but also in humans.
In conclusion, our study demonstrated that myricetin could significantly inhibit migration and invasion of MDA-Mb-231Br cells by suppressing the protein expression of MMP-2/9 and expression of ST6GALNAC5, as well as lung metastasis of breast cancer. We propose that myricetin could be an effective supplement for breast cancer patients, and more detailed investigation regarding its mechanism of action and clinical trials involving its use are warranted.
